Catherine M. Szyman - May 7, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 7, 2023
Transactions value $
-$4,376,616
Form type
4
Date filed
5/9/2023, 07:48 PM
Previous filing
May 4, 2023
Next filing
May 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +4.71K +17.21% $0.00 32.1K May 7, 2023 Direct F1
transaction EW Common Stock Tax liability -$191K -2.15K -6.72% $88.74 29.9K May 7, 2023 Direct
transaction EW Common Stock Tax liability -$122K -1.38K -4.6% $88.74 28.5K May 8, 2023 Direct
transaction EW Common Stock Options Exercise $2.66M +75.6K +264.98% $35.20 104K May 9, 2023 Direct F2
transaction EW Common Stock Sale -$6.72M -75.6K -72.6% $88.94 28.5K May 9, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -4.71K -78.47% $0.00 1.29K May 7, 2023 Common Stock 4.71K Direct F1
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -75.6K -100% $0.00* 0 May 9, 2023 Common Stock 75.6K $35.20 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.
F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023.
F3 This transaction was executed in multiple trades at prices ranging from $88.35 to $89.14 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.